[A17-23] Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2017
Commission awarded on 29.05.2017 by the Federal Joint Committee (G-BA).
Relapsed/refractory Hodgkin lymphoma after autologous stem cell transplantation (ASCT) and treatment with brentuximab vedotin (BV) or after failure of BV therapy if ASCT is not an option
Added benefit not proven due to a lack of suitable data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.